MedTrace Logo

A Phase 1b Study of GKL-006 Injection in Patients With Unresectable Hepatocellular Carcinoma

NCT07713290 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2026-07-20

No results posted yet for this study

Summary

This is a Phase 1b study of GKL-006 Injection in patients with unresectable hepatocellular carcinoma.

Conditions

  • Hepatocellular Carcinoma (HCC)
  • Unresectable Hepatocellular Cancer

Interventions

DRUG

GKL-006 Injection

An iNKT cell therapy

PROCEDURE

Transarterial chemoembolization (TACE)

A standard locoregional therapy for hepatocellular carcinoma

Sponsors & Collaborators

  • Beijing Gene Key Life Technology Co., Ltd

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-03
Primary Completion
2026-11-12
Completion
2027-02-28

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07713290 on ClinicalTrials.gov